Cranberries for preventing urinary tract infections
- 10 November 2023
- journal article
- review article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2023 (11) , CD001321
Abstract
Background Cranberries contain proanthocyanidins (PACs), which inhibit the adherence of p‐fimbriated Escherichia coli to the urothelial cells lining the bladder. Cranberry products have been used widely for several decades to prevent urinary tract infections (UTIs). This is the fifth update of a review first published in 1998 and updated in 2003, 2004, 2008, and 2012. Objectives To assess the effectiveness of cranberry products in preventing UTIs in susceptible populations. Search methods We searched the Cochrane Kidney and Transplant Specialised Register up to 13 March 2023 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Registry Platform (ICTRP) Search Portal and ClinicalTrials.gov. Selection criteria All randomised controlled trials (RCTs) or quasi‐RCTs of cranberry products compared with placebo, no specific treatment or other intervention (antibiotics, probiotics) for the prevention of UTIs were included. Data collection and analysis At least two authors independently assessed and extracted data. Information was collected on methods, participants, interventions and outcomes (incidence of symptomatic UTIs, positive culture results, side effects, adherence to therapy). Risk ratios (RR) with 95% confidence intervals (CI) were calculated where appropriate. Study quality was assessed using the Cochrane risk of bias assessment tool. Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Main results For this update, 26 new studies were added, bringing the total number of included studies to 50 (8857 randomised participants). The risk of bias for sequence generation and allocation concealment was low for 29 and 28 studies, respectively. Thirty‐six studies were at low risk of performance bias, and 23 studies were at low risk of detection bias. Twenty‐seven, 41, and 17 studies were at low risk of attrition bias, reporting bias and other bias, respectively. Forty‐five studies compared cranberry products with placebo, water or no specific treatment in six different groups of participants. Twenty‐six of these 45 studies could be meta‐analysed for the outcome of symptomatic, culture‐verified UTIs. In moderate certainty evidence, cranberry products reduced the risk of UTIs (6211 participants: RR 0.70, 95% CI 0.58 to 0.84; I² = 69%). When studies were divided into groups according to the treatment indication, cranberry products probably reduced the risk of symptomatic, culture‐verified UTIs in women with recurrent UTIs (8 studies, 1555 participants: RR 0.74, 95% CI 0.55 to 0.99; I² = 54%), in children (5 studies, 504 participants: RR 0.46, 95% CI 0.32 to 0.68; I² = 21%) and in people with a susceptibility to UTIs due to an intervention (6 studies, 1434 participants: RR 0.47, 95% CI 0.37 to 0.61; I² = 0%). However, there may be little or no benefit in elderly institutionalised men and women (3 studies, 1489 participants: RR 0.93, 95% CI 0.67 to 1.30; I² = 9%; moderate certainty evidence), pregnant women (3 studies, 765 participants: RR 1.06, 95% CI 0.75 to 1.50; I² = 3%; moderate certainty evidence), or adults with neuromuscular bladder dysfunction with incomplete bladder emptying (3 studies, 464 participants: RR 0.97, 95% CI 0.78 to 1.19; I² = 0%; low certainty evidence). Other comparisons were cranberry products with probiotics (three studies) or antibiotics (six studies), cranberry tablets with cranberry liquid (one study), and different doses of PACs (two studies). Compared to antibiotics, cranberry products may make little or no difference to the risk of symptomatic, culture‐verified UTIs (2 studies, 385 participants: RR 1.03, 95% CI 0.80 to 1.33; I² = 0%) or the risk of clinical symptoms without culture (2 studies, 336 participants: RR 1.30, 95% CI 0.79 to 2.14; I² = 68%). Compared to probiotics, cranberry products may reduce the risk of symptomatic, culture‐verified UTIs (3 studies, 215 participants: RR 0.39, 95% CI 0.27 to 0.56; I = 0%). It is unclear whether efficacy differs between cranberry juice and tablets or between different doses of PACs, as the certainty of the evidence was very low. The number of participants with gastrointestinal side effects probably does not differ between those taking cranberry products and those receiving a placebo or no specific treatment (10 studies, 2166 participants: RR 1.33, 95% CI 1.00 to 1.77; I² = 0%; moderate certainty evidence). There was no clear relationship between compliance with therapy and the risk for repeat UTIs. No difference in the risk for UTIs could be demonstrated between low, moderate and high doses of PACs. Authors' conclusions This update adds a further 26 studies, taking the total number of studies to 50 with 8857 participants. These data support the use of cranberry products to reduce the risk of symptomatic, culture‐verified UTIs in women with recurrent UTIs, in children, and in people susceptible to UTIs following interventions. The evidence currently available does not support its use in the elderly, patients with bladder emptying problems, or pregnant women.Keywords
This publication has 115 references indexed in Scilit:
- Pilot Randomized Controlled Dosing Study of Cranberry Capsules for Reduction of Bacteriuria Plus Pyuria in Female Nursing Home ResidentsJournal of the American Geriatrics Society, 2012
- Recurrent Urinary Tract Infection and Urinary Escherichia coli in Women Ingesting Cranberry Juice Daily: A Randomized Controlled TrialMayo Clinic Proceedings, 2012
- Cranberries vs Antibiotics to Prevent Urinary Tract InfectionsArchives of internal medicine (1960), 2011
- Cranberry Juice Fails to Prevent Recurrent Urinary Tract Infection: Results From a Randomized Placebo-Controlled TrialClinical Infectious Diseases, 2011
- FEASIBILITY OF CRANBERRY CAPSULE ADMINISTRATION AND CLEAN‐CATCH URINE COLLECTION IN LONG‐TERM CARE RESIDENTSJournal of the American Geriatrics Society, 2010
- Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older womenJournal of Antimicrobial Chemotherapy, 2008
- Daily Cranberry Juice for the Prevention of Asymptomatic Bacteriuria in Pregnancy: A Randomized, Controlled Pilot StudyJournal of Urology, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Bioactive compounds in cranberries and their role in prevention of urinary tract infectionsMolecular Nutrition & Food Research, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003